CHARLOTTESVILLE, Va., March 27, 2024 /PRNewswire/ -- AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus.  Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI.

弗吉尼亚州夏洛茨维尔（CHARLOTTESVILLE，Va），2024年3月27日/PRNewswire/-AMPEL BioSolutions宣布了个性化精准医学的突破，这将彻底改变医生管理自身免疫性疾病狼疮的方式。LuGENE®血液检测在同行评审的《基因组医学》杂志上公布，并通过美国的一项后续研究提供给患者，该检测利用预测性人工智能从基因表达预测患者耀斑和药物靶标。

The LuGENE® lab test is now launching at several Lupus practices around the country including those in medical centers, concierge practices and healthcare systems as a practical decision support biomarker test that could greatly impact day-to-day healthcare for patients with Lupus.  The blood test predicts flares before they happen and provides specific information about a patient's disease abnormalities leading to symptoms, allowing physicians to make evidence-based decisions regarding therapy including whether a patient is stable on their current therapeutic regimen.  There are a million and a half lupus patients in the US that could benefit from LuGENE® by preventing unexpected flares and shortening the time to disease-controlling therapy.

LuGENE®实验室测试目前正在全国多家狼疮诊所启动，包括医疗中心、礼宾部和医疗保健系统，作为一种实用的决策支持生物标志物测试，可能会极大地影响狼疮患者的日常医疗保健。血液测试可以在耀斑发生之前预测耀斑，并提供有关导致症状的患者疾病异常的具体信息，从而使医生能够就治疗做出循证决策，包括患者目前的治疗方案是否稳定。美国有150万狼疮患者可以通过预防意外发作和缩短疾病控制治疗时间而受益于LuGENE®。

From RNA gene expression in cells circulating in the blood, LuGENE® identifies real-time abnormalities leading to inflammation and immune system dysfunction that are targetable by medication.  Some abnormalities are well-known and others are novel.  Until now, therapeutic intervention is a trial-and-error endeavor that often takes years until a patient is stabilized without further threat of organ-damaging flares.  LuGENE® clarifies that there are eight subgroups that make up the universe of Lupus patients, the reason why getting the right drug to the right patient at the right time has been so challenging, as until now physicians did not have a tool to know what drug targets are abnormal in their patient.  AMPEL's approach pinpoints the patient subgroup(s) that express the target of one or both of the FDA-approved drugs for lupus, Benlysta and Anifrolumab, providing decision support for physicians to potentially shorten the time to effective therapy and potentially improve quality of life.

根据血液中循环细胞中的RNA基因表达，LuGENE®可识别导致药物可靶向的炎症和免疫系统功能障碍的实时异常。一些异常是众所周知的，另一些是新颖的。到目前为止，治疗干预是一种反复尝试的努力，通常需要数年才能使患者稳定下来，而不会进一步威胁器官破坏。LuGENE®阐明，狼疮患者共有八个亚组，为什么在正确的时间将正确的药物提供给正确的患者是如此具有挑战性，因为到目前为止，医生还没有工具来了解患者体内哪些药物靶标异常。AMPEL的方法确定了表达一种或两种FDA批准的狼疮药物Benlysta和Anifrolumab的目标的患者亚组，为医生提供决策支持，以潜在地缩短有效治疗的时间并潜在地改善生活质量。

Diversity across ancestries is a hallmark of Lupus and the AMPEL R&D team included patients from all ethnicities to ensure that LuGENE® is predictive for all patients in the United States living with Lupus.  This is especially important as Lupus emerges earlier and with greater severity in African-American, Asian, Native-American and Hispanic/Latinx communities shortening life-span.

祖先之间的多样性是狼疮的标志，AMPEL研发团队包括来自所有种族的患者，以确保LuGENE®对美国所有狼疮患者具有预测性。这一点尤其重要，因为狼疮在非裔美国人，亚洲人，美洲原住民和西班牙裔/拉丁裔社区出现得更早，严重程度更高，寿命缩短。

Lupus has been called the 'cruel mystery' because until now doctors have few objective metrics to assess whether their patient is stable with low risk of flare.  Patients with Lupus experience inflammation and pain from their immune system attacking their own organs and tissues with the same vigor as fighting off an infection.  Ninety-five percent of Lupus patients have experienced a flare in the last year.  Symptoms including extreme fatigue and 'brain fog' that impact daily activities, including work and family life, has led to Lupus being referred to as an 'invisible disability'.  A Lupus Foundation of America survey found that fifty-five percent of patients with Lupus reported a complete or partial loss of their income because they no longer are able to work full time due to complications of lupus; one in three have been temporarily disabled by the disease, and one in four currently receive disability payments..

狼疮被称为“残酷的谜”，因为到目前为止，医生几乎没有客观的指标来评估患者是否稳定且眩晕风险低。狼疮患者的免疫系统会以与抵抗感染相同的活力攻击自己的器官和组织，从而产生炎症和疼痛。95%的狼疮患者在过去一年中经历过发作。包括极度疲劳和影响日常活动（包括工作和家庭生活）的“脑雾”在内的症状导致狼疮被称为“无形残疾”。美国狼疮基金会的一项调查发现，55%的狼疮患者报告称，由于狼疮并发症，他们不再能够全职工作，因此他们的收入全部或部分损失；三分之一的人因该疾病暂时致残，四分之一的人目前领取残疾金。

'AMPEL is an industry leader in lupus disease management, and we are excited to unveil our latest advancement in the field of precision medicine,' said Dr. Amrie Grammer, Co-Founder and President/CSO of AMPEL BioSolutions. 'With so many patients experiencing a flare every year, and a high percentage of those cases so severe that they are hospitalized, this is a crucial tool in our fight against Lupus.

AMPEL BioSolutions联合创始人兼总裁/首席运营官AmrieGrammer博士说：“AMPEL是狼疮疾病管理领域的行业领导者，我们很高兴能够公布我们在精准医学领域的最新进展。”由于每年有如此多的患者出现眩晕，并且这些病例中有很大一部分严重到住院治疗，这是我们抗击狼疮的关键工具。

With LuGENE®, healthcare providers will be able to stabilize lupus patients faster than ever before, minimize the occurrence of disruptive flares and hopefully transform Lupus to a chronic condition with increased quality of life.'

有了LuGENE®，医疗保健提供者将能够比以往更快地稳定狼疮患者，最大程度地减少破坏性耀斑的发生，并有望将狼疮转化为慢性病，提高生活质量。”

'Currently, there is no way to predict flares or determine which treatment is most appropriate for each patient, and in many instances it can take many years for some patients to find the most effective one to manage their disease,' said Dr. Peter Lipsky, Co-Founder and CEO/CMO of AMPEL BioSolutions. 'Healthcare professionals can now know whether a flare in disease activity in imminent and if the disease is not controlled, LuGENE® can identify the specific targets of therapies that are more likely to provide relief.

“目前，没有办法预测耀斑或确定哪种治疗方法最适合每位患者，在许多情况下，一些患者可能需要多年才能找到最有效的治疗方法，”博士说。Peter Lipsky，AMPEL BioSolutions的联合创始人兼首席执行官/首席营销官。“医疗保健专业人员现在可以知道疾病活动是否即将爆发，如果疾病得不到控制，LuGENE®可以确定更有可能缓解的治疗的具体目标。

The LuGENE® blood test is a monitoring biomarker that provides essential information to support personalized management for each individual lupus patient.'

LuGENE®血液检测是一种监测生物标志物，可提供必要信息，以支持每位狼疮患者的个性化管理。”

'As a clinician, I am tired of wasting my patients' valuable time and money by trying different therapies for their Lupus using the 'trial and error' methodology, which is our only option now,' said Dr. Don Thomas, Rheumatologist at Arthritis & Pain Associates of Prince George's County in Maryland, author of the Lupus Encyclopedia & Former Chair Advisory council Lupus Foundation of America DC/MD/VA, 'This approach to taking care of Lupus patients ends up causing so much misery as they deal with life-altering symptoms and complications when therapies do not work or cause them side effects.  The dream of using personalized medicine to assist me in choosing therapies that have a greater chance of working, based on their endotype and actual immunologic abnormalities, is closer to becoming a reality with the LuGENE® blood test.'.

马里兰州乔治王子郡关节炎与疼痛协会风湿病学家、《狼疮百科全书》的作者、美国狼疮基金会前主席顾问委员会主席唐·托马斯博士说：“作为一名临床医生，我已经厌倦了用‘试错’的方法来尝试不同的狼疮治疗方法，这是我们现在唯一的选择。”这种治疗狼疮患者的方法最终导致了如此多的痛苦，因为当治疗无效或产生副作用时，他们会处理改变生命的症状和并发症。使用个性化医学来帮助我根据其内型和实际免疫异常选择更有机会工作的疗法的梦想，更接近于通过LuGENE®血液测试实现。

'Lupus is a very complicated disease that is pleomorphic in nature and very difficult to treat,' said Dr. Daniel Wallace, author of Dubois SLE and The Lupus Book & Rheumatologist at Cedars-Sinai, UCLA, Wallace-Lee Center and BoD member of the Lupus Research Alliance affiliate Lupus Therapeutics and LupusLA, 'The LuGENE® blood test is a novel and innovative approach that has the potential to revolutionize the way heterogenous Lupus patients are managed by identifying their genomic biomarker fingerprint and predict if the disease is stable (or not) and what drug targets are abnormal indicating therapeutic options to consider.'

“狼疮是一种非常复杂的疾病，本质上是多形性的，很难治疗，”DanielWallace博士说，他是Dubois SLE的作者，也是加州大学洛杉矶分校Cedars Sinai的狼疮书籍和风湿病学家，Wallace Lee中心和狼疮研究联盟附属狼疮治疗学和LupusLA的BoD成员，“LuGENE®血液检测是一种新颖而创新的方法，有可能通过识别其基因组生物标志物指纹来彻底改变异质性狼疮患者的管理方式，并预测疾病是否稳定（或不稳定），以及哪些药物靶标异常，表明需要考虑治疗方案。”

'I want to express my excitement to be one of the first practices to utilize the LuGENE® genomic biomarker test for Lupus,' Dr. John Tesser, Arizona Arthritis and Rheumatology Associates, 'to potentially manage patients more specifically by being informed if a patient is stable on their current medication or if particular drug targets are abnormal.  AMPEL's Genomic Platform with RNA analytics and machine learning is highly unique and is poised to provide true personalized medicine for patients living with Lupus.

亚利桑那州关节炎和风湿病协会的约翰·特瑟博士说：“我想表达我的兴奋，成为第一批利用LuGENE®基因组生物标志物检测狼疮的实践之一，通过告知患者目前的药物是否稳定或特定的药物靶点是否异常，可以更具体地管理患者。AMPEL的基因组平台具有RNA分析和机器学习功能，非常独特，有望为狼疮患者提供真正的个性化药物。

I am most enthusiastic to participate in the LuGENE® study called ReLATE that will examine the relationship between standard clinical & lab parameters with prediction of flare & abnormal drug targets.'

我最热衷于参加名为ReLATE的LuGENE®研究，该研究将检查标准临床和实验室参数与预测耀斑和异常药物靶标之间的关系。”

'The LuGENE® blood test is incredibly exciting as it represents an important advance towards achieving personalized medicine for Lupus patients by using novel technology of explainable predictive AI and analytics that group all known gene expression by drug target,' Dr. Cindy Aranow, Feinstein Institute at Northwell Health.  'A key part of the AMPEL Genomic approach is subsetting/endotyping patients by their RNA biomarker fingerprint that predict a patient's disease status and potential to flare.  I am delighted to be one of practices that is launching LuGENE® through the ReLATE study.'.

Northwell Health Feinstein研究所的Cindy Aranow博士说：“LuGENE®血液检测令人难以置信地兴奋，因为它代表了通过使用可解释的预测性人工智能和分析新技术，将所有已知基因表达按药物靶标分组，从而实现狼疮患者个性化医疗的重要进展。”。“AMPEL基因组学方法的一个关键部分是通过RNA生物标志物指纹对患者进行亚型/内分型，预测患者的疾病状态和爆发潜力。我很高兴成为通过ReLATE研究推出LuGENE®的实践之一。

'I am excited about the publication describing LuGENE® as a blood test that offers rheumatologists clinically relevant information in real-time predicted by AMPEL's explainable-AI powered RNA analytic platform, that should be highly informative about an individual lupus patient's status,' Dr. Orrin Troum, The Doctors of Saint John's Medical Center, Providence Healthcare  'This approach could provide a real advance in personalized medicine for Lupus patients.  Additionally, I am thrilled to be one of the first practices participating in the LuGENE® study called ReLATE, whose clinical report I anticipate will help me tailor Lupus management.'

“我很高兴有出版物将LuGENE®描述为一种血液检测方法，该方法可实时为风湿病学家提供临床相关信息，由AMPEL可解释的人工智能RNA分析平台预测，该平台应能高度了解狼疮患者的个人状况，”普罗维登斯医疗保健公司圣约翰医学中心的医生Orrin Troum博士说，“这种方法可以为狼疮患者的个性化医疗提供真正的进步。此外，我很高兴成为首批参与名为ReLATE的LuGENE®研究的实践之一，我预计其临床报告将帮助我定制狼疮管理。”

During the interview with Scripps News Network, Dr. Grammer explains how there is currently no way to predict flares or determine which is the most appropriate treatment for an individual lupus patient.  Identifying a therapeutic regimen that stabilizes a patient's disease course often takes several years of trial and error.

在斯克里普斯新闻网的采访中，格拉默博士解释了目前如何无法预测耀斑或确定哪种治疗方法最适合狼疮患者。确定稳定患者病程的治疗方案通常需要几年的反复试验。

LuGENE® is currently available through the ReLATE study at Cedars-Sinai in LA and Arthritis & Osteoporosis Consultants of the Carolinas (AOCC) in Charlotte NC. The study is expanding to sites across the US including Arizona Arthritis & Rheumatology, Feinstein at Northwell Health, Mayo Clinic, Providence Healthcare, Rush in Chicago, Hospital for Special Surgery, Cleveland Clinic, Univ of Maryland, Yale, MetroHealth at Case Western Reserve, U Mass, Duke and others.

LuGENE®目前可通过洛杉矶Cedars Sinai的ReLATE研究和北卡罗来纳州夏洛特的卡罗莱纳州关节炎和骨质疏松症顾问（AOCC）获得。该研究正在扩展到美国各地，包括亚利桑那州关节炎和风湿病，Northwell Health的Feinstein，梅奥诊所，普罗维登斯医疗保健公司，芝加哥拉什，特殊外科医院，克利夫兰诊所，马里兰大学，耶鲁大学，凯斯西储区的MetroHealth，马萨诸塞州，杜克大学等。

Physicians and patients enrolled at these centers will experience how the LuGENE® blood test informs lupus patient management.

在这些中心登记的医生和患者将体验LuGENE®血液检测如何告知狼疮患者管理。

Kathleen Arntsen, Lupus and Allied Diseases Association (LADA) President & CEO, 'For people struggling daily to live with complex autoimmune diseases like Lupus, what motivates us to face another day is the promise and progress of research that will improve our quality of life.  Our community has eagerly awaited the development of more effective therapeutic approaches that can be tailored to each individual.  This groundbreaking LuGENE® blood test has the potential to achieve this goal and transform patient care not only for lupus but for other autoimmune conditions.'

狼疮及相关疾病协会（LADA）主席兼首席执行官凯瑟琳·阿恩特森（KathleenArntsen）说：“对于那些每天都在为狼疮等复杂的自身免疫性疾病而挣扎的人来说，激励我们迎接新的一天的是将改善我们生活质量的研究的承诺和进展。我们的社区迫切期待着开发更有效的治疗方法，可以为每个人量身定制。这项开创性的LuGENE®血液检测有可能实现这一目标，并不仅为狼疮，而且为其他自身免疫性疾病改变患者护理。”

Emmitt Thompson III, Male Lupus Warriors, 'Being able to predict a flare before it happens and get on stabilizing medications for my Lupus is a game changer! As patient who ends up in the ER frequently with organ damaging autoimmunity, I am encouraged by the possibility of getting ahead of Lupus inflammation by monitoring with the LuGENE® blood test.'.

男性狼疮战士埃米特·汤普森三世（EmmittThompsonIII）说：“能够在狼疮发作之前预测到耀斑，并服用稳定狼疮的药物，这将改变游戏规则！作为经常因器官损伤性自身免疫而进入急诊室的患者，我对通过LuGENE®血液检测监测狼疮炎症的可能性感到鼓舞。

Deidre Gee Baptista and Kirsten Gee Maeda, GEE Twins for Lupus and Lupus Foundation of Northern California Board Members: 'With two decades of experiencing the ups and downs of chronic Lupus, we are thrilled for a truly more personalized approach to managing and treating this chronic autoimmune disease.  The LuGENE® blood test provides a much needed, personalized approach to reducing inflammation, pain and what are now 'unpredictable flares'.

北加州狼疮和狼疮基金会董事会成员Deidre Gee Baptista和Kirsten Gee Maeda是Gee双胞胎：“二十年来，我们经历了慢性狼疮的起伏，我们很高兴能有一种真正更个性化的方法来管理和治疗这种慢性自身免疫性疾病。LuGENE®血液测试提供了一种急需的个性化方法，可以减轻炎症，疼痛以及现在“不可预测的耀斑”。

Families navigating their lupus journeys look forward to getting ahead of autoimmune organ damage by getting to an effective treatment more quickly, helping patient's lead productive lives.'

在狼疮旅程中航行的家庭期待着更快地获得有效的治疗，从而提前治疗自身免疫器官损伤，帮助患者过上富有成效的生活。”

Jay Remley, Inaugural Google Cloud Global Dir & Vice-Chair Lupus Foundation NC, 'Lupus is a complex autoimmune disease that is often mis-treated for years, causing pain and anxiety for people living with this lifelong condition.  The LuGENE® blood test may address this critical care need.  One of the most challenging times for a Lupus warrior is the time to establish an initial therapy.  The second most difficult time is the 24x7 anxiety that a patient endures waiting for the inevitable next flare to arrive.  LuGENE® will provide decision support to physicians re whether a patient is stable on the current drug regimen and specifics about what drug targets are abnormal right now, both of which are monumental breakthroughs for the Lupus community.'.

谷歌云全球总监兼狼疮基金会NC副主席杰伊·雷姆利（JayRemley）说，狼疮是一种复杂的自身免疫性疾病，多年来经常被错误治疗，给患有这种终身疾病的人带来痛苦和焦虑。LuGENE®血液检测可以解决这种重症监护需求。狼疮战士最具挑战性的时刻之一是建立初始治疗的时间。第二个最困难的时期是患者忍受的全天候焦虑，等待不可避免的下一次眩晕到来。LuGENE®将为医生提供决策支持，以确定患者目前的药物治疗方案是否稳定，以及目前哪些药物靶标异常的具体情况，这两者都是狼疮社区的重大突破。”。

McKenna Bowes, Molecular Biology Student, 'As an undergraduate student in the Sawalha lab at the Univ. of Pittsburgh (BS, May 2025) and an aspiring medical student, understanding the science behind LuGENE® makes it even more exciting! Even after almost five years of living with lupus, I still find that managing symptoms and trying different medications can be a frustrating and lengthy process.

分子生物学学生McKenna Bowes说，作为匹兹堡大学Sawalha实验室的本科生（BS，2025年5月）和一名有抱负的医学生，了解LuGENE®背后的科学使其更加令人兴奋！即使在狼疮患者中生活了近五年，我仍然发现控制症状和尝试不同的药物可能是一个令人沮丧且漫长的过程。

The ability of the LuGENE® blood test to predict flares and identify different lupus endotypes with the LuGENE® score offers a more personalized and targeted approach to my lupus care, ultimately alleviating some of these challenges for patients overall . I believe that this test can significantly improve the lives of those living with lupus.'.

LuGENE®血液测试能够预测耀斑并通过LuGENE®评分识别不同的狼疮内型，为我的狼疮护理提供了一种更个性化和更有针对性的方法，最终减轻了患者的一些挑战。我相信这项测试可以显着改善狼疮患者的生活。”

Sobia Saleem MA LMFT, Psychotherapist and Lupus Advocate, 'I am beyond thrilled at the launch of the LuGENE®.  As a Lupus patient 10+ years, a blood test that can both predict flares and help my medical team prescribe me targeted therapies that work best with my body is an unprecedented leap. One of my greatest struggles is that Lupus is unpredictable and can rob you of important moments decreasing quality of life due to volatility in disease activity.  To understand a flare is approaching in addition to what pathways are abnormal would be life-changing!  I have wasted literal years of my life in pain because the current model of lupus treatment is a trial-and-error approach.  The LuGENE® blood test solves two of the most unknown variables in a patient's journey,'.

心理治疗师兼狼疮倡导者SobiaSaleemMalmft说，“LuGENE®的推出让我激动不已。作为一名10多年的狼疮患者，一项血液测试既可以预测耀斑，又可以帮助我的医疗团队为我开出对我身体最有效的针对性疗法，这是一项前所未有的飞跃。我最大的困难之一是，狼疮是不可预测的，它会剥夺你的重要时刻，因为疾病活动的波动性会降低生活质量。了解耀斑正在接近，以及哪些途径异常将改变生活！我已经在痛苦中浪费了我的生命，因为目前的狼疮治疗模型是一种反复试验的方法。LuGENE®血液测试解决了患者旅程中两个最未知的变量。

Estela & Juana Mata, Looms For Lupus, 'As advocates for those living with lupus, and as people who live with lupus, we are thrilled about the LuGENE® blood test.  Innovative approaches and precision medicine are crucial new ways to predict flares and manage care. More than exciting scientific advancements, personalized precision medicine is our hope for reducing irreversible damage and complications from unexpected flares.

埃斯特拉和胡安娜·马塔（Estela＆JuanaMata）为狼疮而努力，“作为狼疮患者和狼疮患者的拥护者，我们对LuGENE®血液检测感到兴奋。创新方法和精准医学是预测耀斑和管理护理的关键新方法。个性化精准医学不仅是令人兴奋的科学进步，也是我们减少意外耀斑造成的不可逆转的损害和并发症的希望。

This LuGENE® personalized blood test represents a transformative impact on patient care, giving those living with lupus, and potentially others living with autoimmune conditions, the knowledge of what drug targets are abnormal so they can discuss early treatment opportunities with their doctors to potentially improve quality of life.'

这种LuGENE®个性化血液检测对患者护理产生了革命性的影响，为狼疮患者和可能患有自身免疫性疾病的其他患者提供了关于哪些药物靶标异常的知识，以便他们可以与医生讨论早期治疗机会，以潜在地改善生活质量。”

Christine von Raesfeld, NIH All of Us Ambassador and People with Empathy Founder: 'As a Lupus patient of mixed ancestry, I've experience long-term damage from standard treatments.  I believe LuGENE® offers immense promise for our autoimmune community.  By analyzing our gene expression profile, LuGENE® empowers patients to tailor their treatments, especially crucial for minority populations often underserved by current therapeutic approaches.  Instead of 'trial and error' prevalent in today's standard-of-care, LuGENE® provides a path to targeted treatment that minimizes flares and bridges the gap between science and personalized precision care.'.

美国国立卫生研究院全体大使克里斯汀·冯·雷斯菲尔德（ChristineVonRaesfeld）和“同理心”创始人：“作为一名混合血统的狼疮患者，我经历了标准治疗的长期损害。我相信LuGENE®为我们的自身免疫社区提供了巨大的希望。通过分析我们的基因表达谱，LuGENE®使患者能够定制他们的治疗方法，特别是对于目前治疗方法往往服务不足的少数民族人群来说至关重要。LuGENE®提供了一种靶向治疗的途径，可以最大程度地减少耀斑，弥合科学与个性化精准护理之间的差距，而不是当今护理标准中普遍存在的“反复试验”。

About AMPEL BioSolutions

关于AMPEL BioSolutions

AMPEL is a Precision Medicine company commercializing a development pipeline of blood tests that measure dynamic RNA gene expression providing a real-time CLIA-certified report of inflammation status including drugs targets that are abnormal.  Unlike DNA tests which only need to be done once, AMPEL's RNA blood or biopsy tests are utilized on demand with the goal of 'treat to target' and optimal disease management for Lupus (LuGENE®) or Dermatology Conditions such as Psoriasis or Ezcema (DermaGENE®).  For an otherwise healthy individual, AMPEL's prediction of inflammation with WellGENE® may be an early indicator of changes in the immune system that may be worth investigating further by a trained healthcare provider.  In addition, AMPEL works with Pharma/Biotech customers for target identification, pre-clinical models, post-hoc analysis and real-time enrichment during clinical trial enrollment.  The company's portfolio of tests are supported by the AMPEL Genomic Platform of RNA analytic tools and explainable predictive AI.

AMPEL是一家精密医学公司，将血液测试的开发管道商业化，该测试可测量动态RNA基因表达，提供实时CLIA认证的炎症状态报告，包括异常药物靶标。与只需进行一次的DNA测试不同，AMPEL的RNA血液或活检测试可根据需要使用，目标是“治疗目标”和狼疮（LuGENE®）或牛皮癣或Ezcema（DermaGENE®）等皮肤病的最佳疾病管理。对于其他健康的个体，AMPEL对WellGENE®炎症的预测可能是免疫系统变化的早期指标，可能值得训练有素的医疗保健提供者进一步研究。此外，AMPEL与制药/生物技术客户合作，在临床试验注册期间进行目标识别，临床前模型，事后分析和实时富集。该公司的测试组合得到了RNA分析工具的AMPEL基因组平台和可解释的预测AI的支持。